At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 46 enrolled
Drug / intervention
insulin detemirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 20-week, Randomised, Multi-centre, Open-labelled Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Titration Algorithms (3-0-3 Algorithm and 2-4-6-8 Algorithm) After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment in Korea
In Brief
A Phase 4 clinical trial evaluating insulin detemir for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 46 participants across 6 sites.
Detailed Summary
This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Levemir® (insulin detemir) administered once daily according to two titration algorithms after 20 weeks in subjects with type 2 diabetes inadequately controlled on metformin treatment with or without other anti-diabetic drugs (OADs).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJun 2013
Primary CompletionMay 2015
TodayJul 2026
First PostedJun 4, 2013
Enrollment StartJun 1, 2013
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.1 years ago
Interventions
insulin detemirdrug
Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.